Flash Report 3 minutesRegister for Free AccessCVS Health (CVS) 4Q15 Results: Strong Growth Aided by Acquisitions Coresight Research February 10, 2016 Executive Summary CVS Health reported that 4Q15 net sales rose by 11.0% year over year, to $41.1 billion, slightly above the consensus estimate of $41.0 billion. Diluted non-GAAP EPS rose by 26.5% year over year, to $1.53, which was in line with the consensus estimate and within the guidance range of $1.51–$1.55. Pharmacy sales grew by 11.1%, to $26.5 billion, driven by growth in specialty drugs and the recent $10 billion acquisition of pharmaceutical distributor Omnicare. The company reaffirmed its FY16 forecast of non-GAAP EPS of $5.73–$5.88, in line with consensus of $5.82. For 1Q, CVS expects non-GAAP EPS of $1.14–$1.17, slightly below the consensus estimate of $1.18. Already a subscriber? Log in You are currently viewing a preview of this report. Please select an access option to view the full report. Hide Options - Show Options + Get unlimited access to all our research with one of our subscription plans. View Subscription Plans or Contact us to purchase this report. Contact us ✕ This document was generated for Other research you may be interested in: Next-Generation Product Information Management: From Spreadsheets to AIOctober 2023 China Retail Sales: Year-over-Year Growth Rate Continues To ImproveWeinswig’s Weekly: Temu vs. SheinMarket Navigator: UK Retail, Including E-Commerce—Consumer Constraints To Fuel Multi-Year Discounter Growth